Clinical Trial Update: SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MEK inhibitor selumetinib plus mTOR inhibitor sirolimus for malignant peripheral nerve sheath tumors (MPNST) in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peripheral Nerve Sheath Tumor
• Neurofibromatosis Type

Drugs mentioned

• Selumetinib (selumetinib)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Sarcoma Alliance for Research through Collaboration | Conditions: Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 | Phase 2 | Status: COMPLETED